复发胶质母细胞瘤挽救性立体定向放射外科治疗的结局与预后分层
该回顾性研究纳入1997至2016年53例复发胶质母细胞瘤患者共75个病灶行挽救性立体定向放射外科治疗,中位总生存11.0个月(95%CI 7.1-12.2),中位无进展生存4.4个月(95%CI 3.7-5.0);KPS评分≥80、肿瘤体积<15 cm3及 homogeneity index>1.75 与更长生存独立相关,作者据此提出预后分层模型。
要点
- 挽救性SRS后中位OS为11.0个月,中位PFS为4.4个月。
- KPS≥80与更长OS独立相关;肿瘤体积<15 cm3与更长OS和PFS独立相关。
- homogeneity index>1.75与更长OS和PFS独立相关,作者据此提出预后分组。
核心结论
- SRS与一般状况良好、小体积肿瘤复发及不均匀治疗计划的复发胶质母细胞瘤患者更长OS和/或PFS相关。
- 作者提出一个预后模型以识别可能从SRS获益的复发胶质母细胞瘤患者队列。
研究设计与样本
- 回顾性复习作者所在脑肿瘤数据库(1997-2016年)。
- 53例复发胶质母细胞瘤患者接受挽救性SRS,共治疗75个病灶。
- 主要终点为挽救性SRS后的总生存和無进展生存,采用容积MR图像评估SRS反应。
主要发现
- 中位肿瘤直径2.55 cm,中位肿瘤体积3.80 cm3。
- 中位处方剂量18 Gy(范围12-24 Gy),homogeneity index为1.90(范围1.11-2.02)。
- 挽救性SRS后中位OS估计为11.0个月(95%CI 7.1-12.2),中位PFS为4.4个月(95%CI 3.7-5.0)。
- KPS评分≥80与更长OS独立相关;小肿瘤体积(<15 cm3)和较不均匀治疗计划(homogeneity index>1.75)均与更长OS(p=0.007和0.03)及PFS(分别为p=0.01和0.002)独立相关。
- 基于上述因素识别出2个PFS预后组(5.4 vs 3.2个月),以及3个OS预后组(中位OS分别为15.2 vs 10.5 vs 5.2个月)。
临床怎么用
- 作者提出预后模型用于识别可能从SRS获益的复发胶质母细胞瘤患者队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glioblastoma (GBM) is the most malignant form of astrocytoma. The average survival is 6-10 months in patients with recurrent GBM (rGBM). In this study, the authors evaluated the role of stereotactic radiosurgery (SRS) in patients with rGBMs. METHODS: The authors performed a retrospective review of their brain tumor database (1997-2016). Overall survival (OS) and progression-free survival (PFS) after salvage SRS were the primary endpoints evaluated. Response to SRS was assessed using volumetric MR images. RESULTS: Fifty-three patients with rGBM underwent salvage SRS targeting 75 lesions. The median tumor diameter and volume were 2.55 cm and 3.80 cm3, respectively. The median prescription dose was 18 Gy (range 12-24 Gy) and the homogeneity index was 1.90 (range 1.11-2.02). The median OS after salvage SRS was estimated to be 11.0 months (95% CI 7.1-12.2) and the median PFS after salvage SRS was 4.4 months (95% CI 3.7-5.0). A Karnofsky Performance Scale score ≥ 80 was independently associated with longer OS, while small tumor volume (< 15 cm3) and less homogeneous treatment plans (homogeneity index > 1.75) were both independently associated with longer OS (p = 0.007 and 0.03) and PFS (p = 0.01 and 0.002, respectively). Based on these factors, 2 prognostic groups were identified for PFS (5.4 vs 3.2 months), while 3 were identified for OS (median OS of 15.2 vs 10.5 vs 5.2 months). CONCLUSIONS: SRS is associated with longer OS and/or PFS in patients with good performance status, small-volume tumor recurrences, and heterogeneous treatment plans. The authors propose a prognostic model to identify a cohort of rGBM patients who may benefit from SRS.
引用
- Sharma M, Schroeder JL, Elson P, et al. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. J Neurosurg. 2018. PMID: 30485180. doi:10.3171/2018.4.JNS172909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。